Format

Send to

Choose Destination
J Eval Clin Pract. 2016 Apr;22(2):235-46. doi: 10.1111/jep.12462. Epub 2015 Oct 8.

Statin prescribing according to gender, age and indication: what about the benefit-risk balance?

Author information

1
Section for Social and Clinical Pharmacy, Department of Pharmacy, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
2
Biostatistics, Department of Public Health, University of Aarhus, Aarhus, Denmark.
3
Section for Social and Clinical Pharmacy, University of Copenhagen, Copenhagen, Denmark.
4
Oxford Institute of Population Ageing, University of Oxford, Oxford, UK.
5
General Practice Research Unit, Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway.

Abstract

RATIONALES, AIMS AND OBJECTIVES:

The increasing dispensing of statins has raised concern about the appropriateness of prescribing to various population groups. We aimed to (1) investigate incident and prevalent statin prescribing according to indication, gender and age and (2) relate prescribing patterns to evidence on beneficial and adverse effects.

METHODS:

A cohort of Danish inhabitants (n = 4 424 818) was followed in nationwide registries for dispensed statin prescriptions and hospital discharge information. We calculated incidence rates (2005-2009), prevalence trends (2000-2010) and absolute numbers of statin users according to register proxies for indication, gender and age.

RESULTS:

In 2010, the prevalence became highest for ages 75-84 and was higher in men than women (37% and 33%, respectively). Indication-specific incidences and prevalences peaked at ages around 65-70, but in myocardial infarction, the prevalence was about 80% at ages 45-80. Particularly, incidences tended to be lower in women until ages of about 60 where after gender differences were negligible. In asymptomatic individuals (hypercholesterolaemia, presumably only indication) aged 50+, dispensing was highest in women. The fraction of statin dispensing for primary prevention decreased with age: higher for incident than prevalent prescribing. Independent of age, this fraction was highest among women, e.g. 60% versus 45% at ages 55-64. The fraction for potential atherosclerotic condition (PAC, e.g. heart failure) increased with age.

CONCLUSION:

Prevalence of statin utilization was highest for ages 75-84, although indication-specific measures were relatively low. Despite inconclusive evidence for a favourable risk-benefit balance, statin prescribing was high among people aged 80+, asymptomatic women and PAC patients.

KEYWORDS:

age; benefit-risk balance; gender; guidelines; indication; statin prescribing

PMID:
26446680
DOI:
10.1111/jep.12462
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center